Der var færre gennembrydende Aspergillus infektioner hos patienter, der fik posaconazol forebyggende sammenlignet med kontrolpatienter.
There were fewer breakthrough Aspergillus infections in patients receiving posaconazole prophylaxis when compared to control patients.